Pacira BioSciences, Inc. — Director's Dealing 2021

Jul 30, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Pacira BioSciences, Inc. (PCRX)
CIK: 0001396814
Period of Report: 2021-07-20

Reporting Person: SLONIN JONATHAN (Chief Clinical Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	21350	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$60.96	2031-06-09	Common Stock (14137)		Direct
Stock Option (Right to Buy)	$52.37	2030-07-02	Common Stock (37500)		Direct

Footnotes

F1: Includes 16,905 unvested restricted stock units. The unvested restricted stock units vest as follows: (i) 5,655 restricted stock units that vest in four equal annual installments on June 3, 2022, June 3, 2023, June 3, 2024 and June 3, 2025, and (ii) 11,250 restricted stock units that vest in three equal annual installments on July 1, 2022, July 1, 2023 and July 1, 2024, in each case provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

F2: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.